Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity Bridging of WestVac Recombinant COVID-19 Vaccine (Sf9 Cell) in Healthy Adults
NCT05465785Completed
- Sponsor
- WestVac Biopharma
- Start
- Jul 2022
- Primary completion
- Mar 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial of recombinant COVID-19 (XBB) trimer protein vaccine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by WestVac Biopharma. Primary endpoints: The incidence of adverse reactions (ARs), Anti-SARS-CoV-2 specific neutralizing antibodies Geometric Mean Titer at Day 72 and 1 more. Started Jul 2022; status: completed.
02
Drugs
recombinant COVID-19 (XBB) trimer protein vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05465785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05465785.